Published in Nat Rev Immunol on January 23, 2017
A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection. Cell Rep (2017) 0.75
Human immune system mouse models of Ebola virus infection. Curr Opin Virol (2017) 0.75
Exploring the Immunopathogenesis of Viral Hemorrhagic Fever in Mice with a Humanized Immune System. Front Immunol (2017) 0.75
Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med (2014) 16.45
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 15.15
Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 9.70
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet (2015) 8.12
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature (2014) 6.94
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 6.22
IL-10: the master regulator of immunity to infection. J Immunol (2008) 6.11
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85
Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med (2014) 5.74
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
Human asymptomatic Ebola infection and strong inflammatory response. Lancet (2000) 5.20
Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med (2014) 5.17
Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg (1970) 4.96
Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol (2008) 4.72
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A (2009) 4.38
Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis (1999) 4.18
Inhibition of Lassa and Marburg virus production by tetherin. J Virol (2008) 3.98
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Ebola virus disease in West Africa--clinical manifestations and management. N Engl J Med (2014) 3.73
The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev (2002) 3.69
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis (1999) 3.62
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ (1995) 3.21
Lassa fever. Curr Top Microbiol Immunol (2002) 3.01
Clinical virology of Lassa fever in hospitalized patients. J Infect Dis (1987) 2.94
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med (2016) 2.88
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A (2012) 2.83
Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol (2002) 2.79
Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis (1999) 2.76
Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol (2003) 2.75
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev (2010) 2.64
Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest (2000) 2.45
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science (2015) 2.42
Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol (1997) 2.36
Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis (2009) 2.33
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol (2001) 2.29
Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med (2013) 2.29
Lassa virus. Crit Rev Clin Lab Sci (2004) 2.27
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24
Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol (2012) 2.21
Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol (2010) 2.17
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med (2014) 2.09
Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis (2001) 2.07
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01
Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe (2014) 2.00
The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol (2006) 2.00
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97
Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol (2008) 1.96
Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol (2004) 1.96
Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis (2015) 1.94
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
Lassa fever in West African sub-region: an overview. J Vector Borne Dis (2007) 1.86
Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull World Health Organ (1975) 1.83
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog (2009) 1.78
Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol (2001) 1.75
Effective vaccine for lassa fever. J Virol (2000) 1.74
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72
An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis (1999) 1.67
Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol (2001) 1.65
Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis (2007) 1.63
Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol (2012) 1.63
Biology of the TAM receptors. Cold Spring Harb Perspect Biol (2013) 1.59
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis (2015) 1.57
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis (2012) 1.51
Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med (2015) 1.51
Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis (2009) 1.50
Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A (2015) 1.49
Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol (2009) 1.46
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol (2009) 1.45
Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J Biol Chem (2008) 1.44
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe (2013) 1.42
Ebola hemorrhagic fever and pregnancy. J Infect Dis (1999) 1.41
Principles of regulatory information conservation between mouse and human. Nature (2014) 1.34
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science (2016) 1.29
Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus. Proc Natl Acad Sci U S A (2007) 1.28
Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol (2010) 1.27
Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol (2000) 1.24
Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health (2012) 1.24
Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol (2011) 1.23
The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production. J Virol (2014) 1.22
Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect (2006) 1.20
Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε. J Virol (2012) 1.15
Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppression. J Biol Chem (2013) 1.15